Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies

Br J Dermatol. 2019 May;180(5):1238-1239. doi: 10.1111/bjd.17577. Epub 2019 Jan 15.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antigens, CD20 / immunology
  • Antigens, CD20 / metabolism
  • Autoantibodies / immunology
  • Autoantibodies / metabolism
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism
  • Diagnostic Errors
  • Humans
  • Incidence
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / etiology
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / etiology
  • Male
  • Middle Aged
  • Paraneoplastic Syndromes / diagnosis
  • Paraneoplastic Syndromes / epidemiology*
  • Paraneoplastic Syndromes / immunology
  • Pemphigus / diagnosis
  • Pemphigus / epidemiology*
  • Pemphigus / immunology
  • Rituximab / pharmacology*
  • Rituximab / therapeutic use
  • Skin / drug effects
  • Skin / immunology
  • Stevens-Johnson Syndrome / diagnosis
  • Stevens-Johnson Syndrome / immunology
  • T-Lymphocytes / immunology
  • Undiagnosed Diseases / diagnosis
  • Undiagnosed Diseases / epidemiology*

Substances

  • Antigens, CD20
  • Autoantibodies
  • Rituximab